• +1-646-491-9876
    • +91-20-67278686

    Search

    High Affinity Nerve Growth Factor Receptor-Pipeline Review H1 2017

    High Affinity Nerve Growth Factor Receptor-Pipeline Review H1 2017

    • Report Code ID: RW0001834433
    • Category Pharmaceuticals
    • No. of Pages 99
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H1 2017

    Summary

    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Tropomyosin receptor kinase A or high affinity nerve growth factor receptor is a protein encoded by the NTRK1 gene. High affinity receptor for NGF bind and be activated by NTF3/neurotrophin-3. Upon dimeric NGF ligand-binding undergoes homodimerization, autophosphorylation and activation. It phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation.

    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 2, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Immunology, Dermatology, Ophthalmology and Metabolic Disorders which include indications Osteoarthritis Pain, Breast Cancer, Colorectal Cancer, Pain, Solid Tumor, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Atopic Dermatitis, Bile Duct Cancer (Cholangiocarcinoma) , Brain Cancer, Central Nervous System (CNS) Tumor, Inflammatory Pain, Keratoconjunctivitis sicca (Dry Eye) , Melanoma, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, Pruritus, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Anaplastic Large Cell Lymphoma (ALCL) , Astrocytoma, Biliary Tumor, Chronic Pain, Colon Cancer, Corneal Ulcer (Ulcerative Keratitis/ Eyesore) , Diabetic Retinopathy, Fibrosarcoma, Glioblastoma Multiforme (GBM) , Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Kidney Cancer (Renal Cell Cancer) , Low Back Pain, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Melanoma, Neuropathic Pain, Non-Small Cell Lung Carcinoma, Open-Angle Glaucoma, Ovarian Cancer, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Plaque Psoriasis (Psoriasis Vulgaris) , Pontine Glioma, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Retinitis Pigmentosa (Retinitis) , Sarcomas, Soft Tissue Sarcoma, Tenosynovial Giant Cell Tumor, Thymic Carcinoma and Thyroid Cancer.

    The latest report High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2017, outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
    - The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Overview
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    Allergan Plc
    Array BioPharma Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Daiichi Sankyo Company Ltd
    Dompe Farmaceutici SpA
    Genzyme Corp
    Ignyta Inc
    Loxo Oncology Inc
    Merck & Co Inc
    Nerviano Medical Sciences Srl
    Plexxikon Inc
    Proximagen Ltd
    Purdue Pharma LP
    Rottapharm Biotech Srl
    Tiziana Life Sciences Plc
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles
    AR-523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARRY-954 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7962 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZ-64 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-7451 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNN-27 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cenegermin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CRB-0089 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DS-6051 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    entrectinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GZ-389988 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    larotrectinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    milciclib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NMSP-626 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-7486 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit TrkA for Inflammatory Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize TrkA and TrkB for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit TRK1 for Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SNA-120 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SNA-125 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tavilermide hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VM-902A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Products
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products
    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Product Development Milestones
    Featured News & Press Releases
    May 23, 2017: Dompe Receives Positive CHMP Opinion in Europe For Oxervate (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis
    May 19, 2017: The European Medicines Agency: New medicine for rare eye disease
    May 17, 2017: Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 15, 2017: Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
    May 12, 2017: Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins
    Apr 27, 2017: Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions
    Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma
    Apr 24, 2017: Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
    Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumors
    Apr 05, 2017: Loxo Oncology Announces Acceptance of Larotrectinib Oral Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 04, 2017: Ignyta Announces New Data on Entrectinib at the 2017 AACR Annual Meeting
    Mar 31, 2017: Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017
    Mar 30, 2017: Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
    Mar 28, 2017: Ignyta Announces Presentation of Entrectinib at the 2017 AACR Annual Meeting
    Mar 03, 2017: Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Allergan Plc, H1 2017
    Pipeline by Array BioPharma Inc, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Pipeline by Dompe Farmaceutici SpA, H1 2017
    Pipeline by Genzyme Corp, H1 2017
    Pipeline by Ignyta Inc, H1 2017
    Pipeline by Loxo Oncology Inc, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Nerviano Medical Sciences Srl, H1 2017
    Pipeline by Plexxikon Inc, H1 2017
    Pipeline by Proximagen Ltd, H1 2017
    Pipeline by Purdue Pharma LP, H1 2017
    Pipeline by Rottapharm Biotech Srl, H1 2017
    Pipeline by Tiziana Life Sciences Plc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Discontinued Products, H1 2017
    Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Array BioPharma Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Daiichi Sankyo Company Ltd
    Dompe Farmaceutici SpA
    Genzyme Corp
    Ignyta Inc
    Loxo Oncology Inc
    Merck & Co Inc
    Nerviano Medical Sciences Srl
    Plexxikon Inc
    Proximagen Ltd
    Purdue Pharma LP
    Rottapharm Biotech Srl
    Tiziana Life Sciences Plc

    Request for Sample

    Report Url http://www.reportsweb.com//high-affinity-nerve-growth-factor-receptor-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//high-affinity-nerve-growth-factor-receptor-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//high-affinity-nerve-growth-factor-receptor-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments